OncoCyte Corporation Acquires Insight Genetics

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.

Veracyte Acquires Decipher Biosciences

February 3, 2021

Biotechnology

Veracyte, Inc. has entered into a definitive agreement to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers, for $600 million in total consideration ($250 million cash and up to $350 million in stock). The acquisition expands Veracyte’s genomic cancer diagnostics menu, adds Decipher’s commercial tests and data assets, and is expected to accelerate revenue growth and global market reach.

HiberCell Acquires Genuity Science, Inc.

August 16, 2021

Biotechnology

HiberCell, a clinical-stage oncology company, acquired Genuity Science, a genomics and multi‑omic analytics company with an advanced AI/ML platform, to integrate next‑generation computational capabilities into its translational oncology efforts. The stock acquisition brings Genuity and its subsidiaries into HiberCell, provides approximately $100 million in cash and existing partnership earnouts, and is intended to accelerate HiberCell's clinical programs and expand its preclinical pipeline.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

GraphPad Software / Insightful Science Acquires SnapGene

August 13, 2019

Software

GraphPad Software announced the acquisition of SnapGene and the formation of parent company Insightful Science to house its growing portfolio of scientific R&D software brands. SnapGene — a bioinformatics tool for planning, visualizing, and documenting molecular biology procedures — will operate under the Insightful Science portfolio alongside products such as GraphPad Prism and Geneious.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.